Mavacoxib
Modify Date: 2024-01-06 16:53:56
Mavacoxib structure
|
Common Name | Mavacoxib | ||
|---|---|---|---|---|
| CAS Number | 170569-88-7 | Molecular Weight | 385.336 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 519.8±60.0 °C at 760 mmHg | |
| Molecular Formula | C16H11F4N3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 268.2±32.9 °C | |
Use of MavacoxibMavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs[1]. |
| Name | mavacoxib |
|---|---|
| Synonym | More Synonyms |
| Description | Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs[1]. |
|---|---|
| Related Catalog | |
| Target |
COX-2 |
| In Vitro | Mavacoxib (0-200 μM; 72 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment reduces cell viability in a dose-dependent manner. However, sensitivity to Mavacoxib varied between the cell lines, with IC50 values ranging from 34.5 μM to 157.7 μM. The IC50 values of U2OS, KTOSA5, CSKOS, REM, LILY, K9TCC, K9TCC-AXA, K9TCC-In, K9TCC-Sh, T24, 5637 and HT-1376 cells are 52.6 μM, 89.8 μM, 106.3 μM, 66.6 μM, 97.5 μM, 54.9 μM, 34.5 μM, 78.7 μM, 50.7 μM, 63.4 μM, 72.5 μM and 157.7 μM, respectively[1]. Mavacoxib (0-200 μM; 48 hours; KTOSA5, REM, LILY, K9TCC, U2OS, and T24 cells) treatment can induce caspase-dependent apoptosis in a number of cell lines[1]. Mavacoxib (0-75 μM; 24 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment down-regulates the expression of p-Akt in CSKOS cells in in a dose-dependent manner, as is total Akt in U2OS cells. In REM cells, both p-ERK and p-Akt are increased in expression with increasing doses of Mavacoxib, and in K9TCC cells p-ERK expression is also increased with Mavacoxib treatment[1]. Cell Viability Assay[1] Cell Line: CSKOS, U2OS, REM, K9TCC and T24 cells Concentration: 0 μM, 0.04 μM, 25 μM, 50 μM, 75 μM, 100 μM, 125 μM, 150 μM, 175 μM, 200 μM Incubation Time: 72 hours Result: Cell viability was reduced in a dose-dependent manner. Apoptosis Analysis[1] Cell Line: KTOSA5, REM, LILY, K9TCC, U2OS, and T24 cells Concentration: 0 μM, 50 μM, 100 μM, 200 μM Incubation Time: 48 hours Result: Induced apoptosis in canine and human cancer cell lines. Cell Viability Assay[1] Cell Line: CSKOS, U2OS, REM, K9TCC and T24 cells Concentration: 0 μM, 25 μM, 50 μM or 75 μM Incubation Time: 24 hours Result: In CSKOS cells, p-Akt was downregulated, as was total Akt in U2OS cells. In REM cells, both p-ERK and p-Akt were increased in expression, and in K9TCC cells p-ERK expression was also increased. |
| In Vivo | Osteoarthritic dogs enrolled in the studies are randomized to receive treatment with Mavacoxib and daily placebo for carprofen or placebo for Mavacoxib and daily carprofen at a nominal dose of 4 mg/kg BW. Mavacoxib is administered in both studies with a 2-week interval between the first and second doses but with monthly dosing thereafter. The nominal Mavacoxib doses in Studies 1 and 2 are 4 and 2 mg/kg BW, respectively. Seven Mavacoxib doses are administered in Study 1, but only five doses in Study 2. In Study 1, Mavacoxib is administered without regard to the timing of meals, but in Study 2, all of the Mavacoxib doses are administered with food[2]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 519.8±60.0 °C at 760 mmHg |
| Molecular Formula | C16H11F4N3O2S |
| Molecular Weight | 385.336 |
| Flash Point | 268.2±32.9 °C |
| Exact Mass | 385.050812 |
| PSA | 86.36000 |
| LogP | 3.69 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.603 |
| Storage condition | 2-8°C |
|
~78%
Mavacoxib CAS#:170569-88-7 |
| Literature: Sun, Changquan; O'Connor, Garry Patent: US2005/222240 A1, 2005 ; Location in patent: Page/Page column 5 ; |
|
~%
Mavacoxib CAS#:170569-88-7 |
| Literature: Journal of Medicinal Chemistry, , vol. 40, # 9 p. 1347 - 1365 |
|
~%
Mavacoxib CAS#:170569-88-7 |
| Literature: Journal of Medicinal Chemistry, , vol. 40, # 9 p. 1347 - 1365 |
|
~%
Mavacoxib CAS#:170569-88-7 |
| Literature: US5466823 A1, ; US 5466823 A |
|
~%
Mavacoxib CAS#:170569-88-7 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 20, # 15 p. 4653 - 4660 |
| 4-[5-(4-Fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide |
| 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide |
| Mavacoxib |
| PHA 739,521 |
| Benzenesulfonamide, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- |